{"id":"https://genegraph.clinicalgenome.org/r/ca1bbfdc-aeb5-4274-ad8f-f3d14732c990v2.0","type":"EvidenceStrengthAssertion","dc:description":"*HAL* was first reported in relation to autosomal recessive histidinemia in 2005 (Kawai Y, et al., 2005, PMID: 15806399). The disease was first described by Ghadimi et al in 1961, who observed elevated levels of histidine in blood and urine of two patients. This metabolic disorder seems to be benign in most affected individuals, although, under unusual circumstances, the disorder may be harmful and produce the central nervous system disease noted in a few histidinemic patients (Reviewed in Levy H., Histidinemia. Orphanet encyclopedia, May 2002). HAL catalyzes the reaction: L-histidine = urocanate + NH3; in patients with deficiency of HAL there is a consequent accumulation of histidine and decreased concentration of urocanate. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Biallelic missense variants in this gene have been reported in at least 1 proband in 1 publication (PMID: 15806399). At least 7 additional variants (splice site, nonsense, missense, and frameshift) have been associated with mildly increased histidine levels in the heterozygous state (PMIDs: 25575548, 27453504, 26990548). This gene-disease relationship is supported by the biochemical function of HAL which is consistent with the biochemical abnormalities observed in individuals with histidinemia (Takeuchi, J. Biochem., Japan, 34, 1 (1941)), the functional alteration in patient cells (PMID: 7211776) and the biochemical features of a histidinemic mouse (PMID: 8486363). In summary, there is limited evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.\n\nThis gene-disease pair was previously evaluated by the Aminoacidopathy GCEP on 09/25/2020. It was reevaluated on 10/24/2023. As a result of this reevaluation, the classification remained Limited with no new evidence identified.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/ca1bbfdc-aeb5-4274-ad8f-f3d14732c990","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb","calculatedEvidenceStrength":"Limited","changes":[{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"},{"id":"cg:sopChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2023-11-17T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2023-12-08T17:41:08.298Z","role":"Publisher"}],"curationReasons":["RecurationTiming"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00be02e3-94da-4296-90ee-a5737ce59edf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00be02e3-94da-4296-90ee-a5737ce59edf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15806399","rdfs:label":"Patient 3","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/9563ed34-d282-4d45-ac6e-1f05db40762f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002108.4(HAL):c.965G>C (p.Arg322Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115146"}},{"id":"https://genegraph.clinicalgenome.org/r/6f784bdd-1362-42d8-8bc0-fe0452c68165","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002108.4(HAL):c.776_777delinsTG (p.Pro259Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139532293"}}],"detectionMethod":"Exons 1â€“21 and the flanking sequences of the histidase gene were amplified by polymerase chain reaction and screened for the presence of small mutations. Mutations were characterized by nucleotide sequencing whenever a heteroduplex band was detected.","firstTestingMethod":"PCR","phenotypeFreeText":"Detected as having high histidine levels (>6mg/dl) by the neonatal screening program","phenotypes":"obo:HP_0010906","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/3f65b51b-2038-4c5c-8b09-33e41b46e729_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15806399","allele":{"id":"https://genegraph.clinicalgenome.org/r/9563ed34-d282-4d45-ac6e-1f05db40762f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/84df5443-b2fe-4a0b-a7a6-1f48563f0aee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15806399","allele":{"id":"https://genegraph.clinicalgenome.org/r/6f784bdd-1362-42d8-8bc0-fe0452c68165"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/84df5443-b2fe-4a0b-a7a6-1f48563f0aee","type":"EvidenceLine","dc:description":"This variant, of paternal origin, occurs at a conserved residues and is suspected to affect secondary structure.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84df5443-b2fe-4a0b-a7a6-1f48563f0aee_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3f65b51b-2038-4c5c-8b09-33e41b46e729","type":"EvidenceLine","dc:description":"This variant, of maternal origin, occurs at a conserved residues and is suspected to affect secondary structure.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f65b51b-2038-4c5c-8b09-33e41b46e729_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e8ca2a5-d30f-4385-9516-652da48ea2b1","type":"EvidenceLine","dc:description":"Histidine ammonia-lyase activity in skin homogenate was measured by conversion of histidine to urocanic acid. This reaction was previously characterized by Takeuchi in 1941 (J. Biochem., Japan, 34, 1 (1941); no PMID available) using histidine ammonia-lyase purified from liver extract. While this function is highly consistent with the histidinemia phenotype this disease mechanism has not been well established in molecularly characterized patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/160172c4-3d53-48d5-ac1b-1d67ef6aa7a6","type":"Finding","dc:description":"The role of HAL in the catabolism of histidine is consistent with the elevated levels detected in patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7211776","rdfs:label":"Histidine ammonia-lyase activity","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb21b573-37d4-4a41-8fb4-4562fe2e5ce1","type":"EvidenceLine","dc:description":"The alteration of histidine ammonia-lyase activity is consistent with the histidinemia see in patients.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e471d366-7af6-4d0c-86ea-3a535c438665","type":"FunctionalAlteration","dc:description":"Histidine ammonia-lyase activity, measured by conversion of histidine to urocanic acid, was significantly reduced in patient cells, <10% that of control children (with intermediate levels in heterozygotes).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7211776","rdfs:label":"histidine ammonia-lyase activity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c5764eb8-2aad-419e-be57-99f8c6859ebb_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20ddddad-413c-417c-b83b-a3a457920cc4","type":"EvidenceLine","dc:description":"This naturally occurring mouse model was was previously characterized by Kacser et al., 1973 (PMID: 4583487) and here identified homozygous for the Arg322Gln variant. Further study by Mellor et al., 2004 (PMID: 15287859) demonstrated that in vivo liver transduction with WT histidase restored histidase activity towards normal levels.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffc699f6-2a11-4472-a354-202af678d51e","type":"Finding","dc:description":"As in humans, mice with histidinemia have elevated histidine in body fluids and decreased histidase activity in liver and skin.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8486363","rdfs:label":"Histidinemic Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Limited","sequence":7231,"specifiedBy":"GeneValidityCriteria9","strengthScore":4.2,"subject":{"id":"https://genegraph.clinicalgenome.org/r/sJinfAf1XPI","type":"GeneValidityProposition","disease":"obo:MONDO_0009345","gene":"hgnc:4806","modeOfInheritance":"obo:HP_0000007"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c5764eb8-2aad-419e-be57-99f8c6859ebb-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}